📢 Prostate cancer specialists wanted Help refine an e-learning resource to support clinician–patient discussions and informed decision-making about active surveillance and treatment options for low/intermediate-risk prostate cancer. 90–120 min online focus group + £60. Register: buff.ly/qa3Cocf

🩺 NHS England needs clinical & technical experts to join the evaluation panels for the PET-CT Phase 1 Procurement - shaping 50% of England's provision for the next 10 years. Looking for: - Radiologists / NM Physicians - Referring Consultants - Radiographers / Technologists - MPEs (1/2) 👇

We're here to support anyone affected by prostate cancer - whether they need information about a diagnosis, someone who's had treatment to talk to, or help with side effects. We'll cover our support services in this webinar. 📅 24 June 🕕️ 6pm–7.30pm Signpost to patients: buff.ly/Cqxxr1W

From the 29th June, The Patients Association will be hosting free webinars as part of Patient Partnership Week. This will bring together patients, professionals, policymakers, and researchers to explore what meaningful partnership looks like in practice. More information here ➡️ buff.ly/TLwgPdU

What do the latest UK NSC recommendation on prostate cancer screening and TRANSFORM trial expansion mean for practice? Read our summary for health professionals, access FAQs and share your feedback: buff.ly/U2UnXx3

Please share with patients our free webinar. Our upcoming webinar will help men feel less alone and more supported after a prostate cancer diagnosis, with information about our services available and insight from others with lived experience. 📅 24 June 🕕 6pm–7:30pm Details here: buff.ly/cX658LF

Dr Alan McWilliam @manchester.ac.uk leads a #research team working to make #radiotherapy treatment more precise. Since 2021, we’ve supported his team to develop a way to more quickly identify men with #ProstateCancer who are not responding to treatment. 📙 Read more: buff.ly/fQjCGRM

NICE is recruiting a professional member for the Prostate Cancer: Diagnosis & Management committee. If you’re a health or social care professional with relevant expertise, this is a great chance to influence national guidance and improve patient outcomes. Read more & apply ➡️ buff.ly/qwyLij3

Macmillan and @rc-pharm.bsky.social are seeking healthcare professionals’ views on managing medicines and polypharmacy during cancer care. Your insights will help improve medicines optimisation, patient support and care for people affected by cancer. Take the survey ➡️ buff.ly/yIrGMoV

Professor Val Macaulay @ndsurgicalsci.bsky.social led a research group investigating the role of IGF‑1 in #ProstateCancer. Since 2004, we’ve supported her team to explore whether drugs targeting IGF‑1 could help slow the growth of localised prostate cancer. 📙 Read more: buff.ly/GyaDLdr

Could measuring ctDNA & serum PSA identify men with advanced #ProstateCancer who may benefit from treatment intensification? A team @ucl.ac.uk & the University of Trento, led by Profs Francesca Demichelis & Gert Attard, publish findings in @natcancer.nature.com. Grab a ☕ & read: lnkd.in/eeSkYZVX

Dr Robert Kypta at @imperialcollegeldn.bsky.social leads a team exploring novel treatments for #ProstateCancer. Since 2022, we’ve supported his team to develop a new targeted drug delivery approach, helping protect healthy cells and reduce side effects. Read more 📙: bit.ly/4u2x383

📢 Introducing Dr Shaun Scaramuzza, the first of our 2025 Career Acceleration Fellows! 🔬 Shaun’s research aims to improve early detection and treatment options for men at highest risk. Our 2026 round is still open for applications! You can apply here: buff.ly/3fXLLUz

Dr Susan Heavey at @ucl.ac.uk leads a team focused on making drug development more effective. Since 2018, we’ve supported her team to use patient‑derived explants & spatial transcriptomics to identify the most promising #ProstateCancer treatments. 📙 Read more: bit.ly/2ADGYs9

Could PSA levels measured during & after treatment, together with radiological features, help guide personalised treatment decisions for men with #ProstateCancer? A team led by Prof Gert Attard @ucl.ac.uk share new findings in @thelancetoncol.bsky.social. Grab a ☕️ & read: doi.org/10.1016/S147...

Strengthening the UK #prostatecancer clinical research pipeline.🔬 Our April in person CRSG meeting sparked rich discussion on major research proposals & UK wide collaboration. Huge thanks to our proposal presenters, CRSG and Early Career members. 👏 📙https://bit.ly/4mGKnfK

How have the PACE trials influenced radiotherapy treatment for #ProstateCancer? Profs Nicholas van As & @profemmahall.bsky.social @icr.ac.uk share learnings from a decade of trials, including Prostate Cancer UK-funded PACE-NODES, in @ijrobp.bsky.social. Grab a ☕ & read: doi.org/10.1016/j.ij...

The April edition of Research News is here! Read about: 💙 The TRANFORM screening trial. 📢 Our new LinkedIn channel for prostate cancer researchers. 🔬 Research stories with impact. 🏆 Researcher achievements. 💰 Funding opportunities. Read it here 📰 : buff.ly/k09eMvo

Prostate Cancer UK funded a team led by Prof Noel Clarke at the Movember FASTMAN Centre of Excellence to analyse bone scans from the STAMPEDE trial. They explored whether adding radiotherapy to the prostate could help men whose cancer had spread. 📙 prostatecanceruk.org/research/res...

🥼 Professor Simon Mackay @unistrathclyde.bsky.social leads a team developing new treatments for men with advanced #ProstateCancer. 💊 In 2019, we funded Simon to further develop his first-in-class IKKα inhibitor. 📙 Read more about Simon's innovative #research: prostatecanceruk.org/research/res...

📣 Job Opportunity: Biobank Manager for TRANSFORM Discovery. Play a central role in developing a world-leading high-quality data & tissue resource and help TRANSFORM outcomes for men affected by #ProstateCancer. Full details ⤵️ www.imperial.ac.uk/jobs/search-...

Could hypoxia and angiogenesis gene expression help personalise #ProstateCancer radiotherapy? Funded by our Movember FASTMAN Centre of Excellence, Prof Hoskin and Prof Choudhury @christieinstitute.bsky.social share new findings in Clinical Oncology. Grab a ☕ and read: bit.ly/4sHE25b

Our final Patient Research Partner speech comes from Patrick. Diagnosed with Stage 4 #ProstateCancer in 2020, Patrick is dedicated to raising awareness, visiting many organisations and businesses. A huge thank you to all of our inspirational Patient Research Partners 👏

It’s time for the final session of From Ideas to Innovation 2026 🗣️ The focus is on advanced #ProstateCancer, and we’re delighted to be joined by speakers Professor Gerhardt Attard, Dr Ashwin Sachdeva and Dr Emily Grist.

Kicking off the first session of the afternoon 🎤 Simon and Hayley from our research team are sharing how @prostatecanceruk.bsky.social can support researchers - from making key introductions, to our open access reimbursement scheme, to helping their work reach the audiences that matter.

Derek’s father died from oligometastatic #ProstateCancer, before Derek was diagnosed with the disease himself some years later. After his surgery, Derek began volunteering for @prostatecanceruk.bsky.social and served as a patient representative on our research committees for over 10 years.

Next up is a session on primary and metastatic cancer. Great to welcome Professor Charlotte Bevan and PhD student Nuria Fortuno from Imperial College London (@IP-London.bsky.social). ➡️ Find out more about their work: bit.ly/46Bqsal

Our first Patient Research Partner today is Vincent. Shortly after retiring, he was diagnosed with #ProstateCancer, with no symptoms beforehand. After a radical robotic prostatectomy and excellent care, he achieved a curative outcome with minimal side effects.

We’re now in the auditorium for the first session of Day 2 🎤 Our Director of Research, Dr Matthew Hobbs, opens the day with an update on work to develop the @prostatecanceruk.bsky.social 10-year research strategy.

A great first day at From Ideas to Innovation! 👏 Following a day of talks exploring the latest research in risk, treatment resistance, screening, and imaging, the first poster session is now underway—showcasing a wide range of high quality prostate cancer research.

Our final Patient Research Partner talk of the day comes from Robert. Successfully treated for #ProstateCancer in 2003, he served on Prostate Cancer UK’s Research Advisory Group, PPI and Research Strategy groups until 2025, and has supported fundraising events including #MarchforMen.

We close the day with a session on imaging and staging in #ProstateCancer. Professor Hashim Ahmed (@londonprostate1.bsky.social) and Dr Martin Connor from @ip-london.bsky.social are joining us to share more about their work in this area. ➡️ Find out more: bit.ly/4moUAwq

Our next session explores barriers to thriving in the #ProstateCancer research community, with opening reflections from Black researchers. We’ll also explore practical ways the community can drive positive change and ensure everyone can thrive and make an impact for men.

Sue’s husband was diagnosed with #ProstateCancer at 52. After running out of licensed treatment options, he joined a Phase 3 abiraterone trial that extended his life and improved his quality of life. It inspired Sue’s passion for research, early diagnosis and better treatment.

Our next session is all about TRANSFORM - the biggest #ProstateCancer screening trial in 20 years. Thanks to Professor Rakesh Heer, Professor Rhian Gabe, and Dr Nikhil Mayor (@nikhilmayor.bsky.social) for speaking. ➡️ Learn more: bit.ly/3xSHfYS @ip-london.bsky.social

Robin is our next Patient Research Partner on stage at the @royalcollegeofgps.bsky.social. Diagnosed with low-risk, localised #ProstateCancer in 2006, he has been a volunteer with Prostate Cancer UK since 2008 and has served on national research and funding committees as a patient representative.

After a short break, we're back underway with our next session on #ProstateCancer risk. Speakers Professor Colin Cooper and Mr Harveer Dev are part of a team using genetic data to predict progression and reduce recurrence. ➡️Find out more: bit.ly/4ecqVoZ

Each of our sessions features a Patient Research Partner - men affected by #ProstateCancer or their families. First up is Simon, diagnosed in 2011 aged 49. He’s taken on many fundraising challenges, raising thousands for charity - including £45,000 for Prostate Cancer UK in 2018.

Our first session explores treatment resistance in #ProstateCancer. Two of today’s speakers: Professor Johann de Bono and Dr Alec Paschalis, work in this area alongside @asharpmedonc.bsky.social ➡️ Find out more: bit.ly/4c9IzHm

Our From Ideas to Innovation meeting is officially underway! 🎉 Thrilled to see researchers arriving this morning at @royalcollegeofgps.bsky.social for a full programme of research presentations, networking and insightful discussions.

Could RNA-targeting identify drivers of AR-V7 linked #ProstateCancer? A team including Prof de Bono @icr.ac.uk, supported by our Movember London Centre of Excellence, share new findings as part of a @jci.org double-header. Grab a ☕ and read: bit.ly/4cjfadS

📣 Announcing the Trailblazers in Cancer Research Meeting Bringing together the British Association for Cancer Research early career community to share research, network, and hear from renowned cancer researchers. 📍 Manchester 🗓️ 26–27 November 2026 Read more 👉 bacr.org.uk/event/save-t...

📢 Upcoming European Prostate Cancer Alliance webinar! This webinar will focus on epigenetics in #ProstateCancer, with confirmed speakers including Prof Wilbert Zwart @zwartlab.bsky.social, Prof Leigh Ellis, and Filipa Moreira Silva. 📆 Monday 22 June 2026, 15:00-17:15

📢 Final week to apply for a prestigious £2M Trailfinders Prostate Cancer UK Senior Clinical Fellowship and become a future leader in medical oncology. 📅 Deadline: 20 April Find out more here:

📣 The Tumour Microenvironment Meeting & 3D Cancer Modelling Workshop 2026, run by the @thebacr.bsky.social, highlights key advances in the field, from spatial mapping to clinical translation. 📍 University of Nottingham, 8–10 July 🗓️ Abstract deadline: 17 April Read more 👉 lnkd.in/ejMaR3ct

@garethrichards.bsky.social @sheffielduni.bsky.social wants to develop new, innovative ways to monitor and treat #ProstateCancer. In 2022, we funded Gareth to explore adrenomedullin as a biomarker and therapeutic target for prostate cancer. 📙Read more here: prostatecanceruk.org/research/res...

📢 We're seeking proposals from ambitious medical oncologists aiming to become a sector-leading Trailfinders Prostate Cancer UK Professor in Prostate Cancer. Deadline: 20 April Find out more here: 👉

📚 Update your knowledge and practice New, free online course on Early Detection in Prostate Cancer in collaboration @bmj.com. Topics include: 🔹Risk 🔹PSA testing 🔹Patient referral & more ⭐ Earn 1 CPD point Start learning ➡️ buff.ly/1erx4gI #prostatecancer #CPD

Could AR mutation status serve as a predictive biomarker for AR‑targeted therapies in #ProstateCancer? A team led by Prof de Bono at @icr.ac.uk, supported by our Movember London Centre of Excellence, share findings in @jci.org. Grab a ☕ & read: doi.org/10.1172/JCI1...

Could blocking key epigenetic androgen receptor co-regulators be a potential new treatment for advanced #ProstateCancer? Prof. Nigel Mongan @uniofnottingham.bsky.social and team share promising novel findings in @moloncology.bsky.social. Grab a ☕ and read: doi.org/10.1002/1878...